Emergent Biosolutions resumes COVID-19 vaccine production
July 29, 2021 at 12:40 PM EDT
Emergent BioSolutions said Thursday it will resume manufacturing bulk drug substances for Johnson & Johnson's COVID-19 vaccine after an extensive review prompted by the ruining of millions of doses at one of its plants.
